<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Zolmitriptan</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00315</strong>&#160; (APRD00376)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Zolmitriptan is a synthetic tryptamine derivative and appears as a white powder that is readily soluble in water. [Wikipedia]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00315/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00315/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00315.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00315.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00315.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00315.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00315.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00315">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>(S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IUPAC</td></tr><tr><td>Zolmitriptan</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>USAN, BAN</td></tr><tr><td>Zolmitriptanum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>AscoTop</td><td>AstraZeneca</td></tr><tr><td>Nomi</td><td>Square</td></tr><tr><td>Zolmiles</td><td>Actavis</td></tr><tr><td>zolmiptriptan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Zolmit</td><td>Beximco</td></tr><tr><td>Zomig</td><td>AstraZeneca</td></tr><tr><td>Zomig Rapimelt</td><td>AstraZeneca</td></tr><tr><td>Zomigon</td><td>AstraZeneca</td></tr><tr><td>Zomigoro</td><td>AstraZeneca</td></tr><tr><td>Zomitan</td><td>Incepta</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/serotonin-antagonists">Serotonin Antagonists</a></li>
<li><a href="/mesh/serotonin-5-ht1-receptor-agonists">Serotonin 5-HT1 Receptor Agonists</a></li>
<li><a href="/mesh/serotonin-receptor-agonists">Serotonin Receptor Agonists</a></li>
<li><a href="/mesh/anti-migraine-agents">Anti-migraine Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>139264-17-8</td></tr><tr><th>Weight</th><td>Average: 287.3568<br>Monoisotopic: 287.163376931</td></tr><tr><th>Chemical Formula</th><td>C<sub>16</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>ULSDMUVEXKOYBU-ZDUSSCGKSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CN(C)CCC1=CNC2=CC=C(C[C@H]3COC(=O)N3)C=C12</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Indoles and Derivatives</td></tr><tr><th>Subclass</th><td>Tryptamines and Derivatives</td></tr><tr><th>Direct parent</th><td>Tryptamines and Derivatives</td></tr><tr><th>Alternative parents</th><td>Indoles; Oxazolidinediones; Benzene and Substituted Derivatives; Substituted Pyrroles; Tertiary Amines; Carbamic Acids and Derivatives; Polyamines</td></tr><tr><th>Substituents</th><td>indole; oxazolidinedione; substituted pyrrole; benzene; pyrrole; oxazolidine; carbamic acid derivative; tertiary amine; polyamine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the tryptamines and derivatives. These are compounds containing the tryptamine backbone, which is structurally characterized by an indole ring subsituted at the thrid position by an ethanamine.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the acute treatment of adult migraine with or without auras.</td></tr><tr><th>Pharmacodynamics</th><td>Zolmitriptan is a selective agonist of serotonin (5-hydroxytryptamine; 5-HT) type 1B and 1D receptors. It is structurally and pharmacologically related to other selective 5-HT1B/1D receptor agonists, and has only a weak affinity for 5-HT<sub>1A</sub>, 5-HT<sub>5A</sub>, and 5-HT<sub>7</sub> receptors and no significant affinity or pharmacological activity at 5-HT<sub>2</sub>, 5-HT<sub>3</sub> or 5-HT<sub>4</sub> receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Zolmitriptan also activates 5-HT<sub>1</sub> receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Zolmitriptan in humans.</td></tr><tr><th>Mechanism of action</th><td>Zolmitriptan binds with high affinity to human 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors leading to cranial blood vessel constriction. Current theories proposed to explain the etiology of migraine headache suggest that symptoms are due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of zolmitriptan for the treatment of migraine headache can most likely be attributed to the agonist effects at the 5HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.</td></tr><tr><th>Absorption</th><td>Mean absolute oral bioavailability is approximately 40%. Food has no affect on the rate and extent of absorption.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>8.4&#177;3.3 L/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td>25%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. There have been three metabolites identified: indole acetic acid, N -oxide, and N-desmethyl metabolites. However, the N-desmethyl is the only active metabolite.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Zolmitriptan</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li></ul></td><td><a href="/metabolites/DBMET00276">norzolmitripan</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/277">Details</a></td></tr><tr><td>Zolmitriptan</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00497">Indole acetic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/511">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>The mean elimination half-life of zolmitriptan and of the active N-desmethyl metabolite is 3 hours.</td></tr><tr><th>Clearance</th><td><ul>
	<li>25.9 mL/min/kg</li>
</ul></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3<br>Gene symbol: GNB3<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P16520" target="_blank">P16520 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs5443" target="_blank">rs5443 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>T Allele</td><td>Better response to drug treatment</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/17361120" target="_blank" title="Schurks M, Kurth T, Stude P, Rimmbach C, de Jesus J, Jonjic M, Diener HC, Rosskopf D: G protein beta3 polymorphism and triptan response in cluster headache. Clin Pharmacol Ther. 2007 Oct;82(4):396-401. Epub 2007 Mar 14.">17361120 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8956</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8957</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6888</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8782</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8383</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7674</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8051</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5822</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6189</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8989</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8281</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.831</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8481</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9263</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7651
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9641
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9961
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5965 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9301
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8949
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Astrazeneca pharmaceuticals lp</li>
<li>Ipr pharmaceuticals inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.astrazeneca.ca">AstraZeneca Inc.</a></li>
<li><a href="http://www.cimalabs.com">Cima Laboratories Inc.</a></li>
<li><a href="http://www.iprpharmaceuticals.com">IPR Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Promex Medical Inc.</li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Spray</td><td>Nasal</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00918">Almotriptan</a></td><td>Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and almotriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.</td></tr><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>Use of two serotonin modulators, such as zolmitriptan and amitriptyline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00543">Amoxapine</a></td><td>Use of two serotonin modulators, such as zolmitriptan and amoxapine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01200">Bromocriptine</a></td><td>Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, bromocriptine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. 
Use of two serotonin modulators, such as zolmitriptan and bromocriptine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00490">Buspirone</a></td><td>Use of two serotonin modulators, such as zolmitriptan and buspirone, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00248">Cabergoline</a></td><td>Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, carbergoline, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. 
Use of two serotonin modulators, such as zolmitriptan and carbergoline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00215">Citalopram</a></td><td>The use of two serotonin modulators, such as zolmitriptan and citalopram, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB01242">Clomipramine</a></td><td>Use of two serotonin modulators, such as zolmitriptan and clomipramine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB03225">D-Tryptophan</a></td><td>Use of two serotonin modulators, such as zolmitriptan and D-tryptophan, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>Use of two serotonin modulators, such as zolmitriptan and desipramine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB06700">Desvenlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00514">Dextromethorphan</a></td><td>Use of two serotonin modulators, such as zolmitriptan and dextromethorphan, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00320">Dihydroergotamine</a></td><td>Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, dihydroergotamine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.</td></tr><tr><td><a href="/drugs/DB01142">Doxepin</a></td><td>Use of two serotonin modulators, such as zolmitriptan and doxepin, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00476">Duloxetine</a></td><td>Use of two serotonin modulators, such as zolmitriptan and duloxetine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00216">Eletriptan</a></td><td>Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and eletriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.</td></tr><tr><td><a href="/drugs/DB01049">Ergoloid mesylate</a></td><td>Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, ergoloid mesylate, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. </td></tr><tr><td><a href="/drugs/DB01253">Ergonovine</a></td><td>Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, ergonovine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. </td></tr><tr><td><a href="/drugs/DB00696">Ergotamine</a></td><td>Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, ergotamine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.</td></tr><tr><td><a href="/drugs/DB01175">Escitalopram</a></td><td>Use of two serotonin modulators, such as zolmitriptan and escitalopram, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Use of two serotonin modulators, such as zolmitriptan and fluoxetine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Use of two serotonin modulators, such as zolmitriptan and fluvoxamine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00998">Frovatriptan</a></td><td>Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and frovatriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.</td></tr><tr><td><a href="/drugs/DB00614">Furazolidone</a></td><td>The MAO inhibitor, furazolidine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing furazolidine are contraindicated. </td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>Use of two serotonin modulators, such as zolmitriptan and imipramine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>The MAO inhibitor, isocarboxazid, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing isocarboxazid are contraindicated.</td></tr><tr><td><a href="/drugs/DB00150">L-Tryptophan</a></td><td>Use of two serotonin modulators, such as zolmitriptan and L-tryptophan, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00601">Linezolid</a></td><td>The MAO inhibitor, linezolid, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing linezolid are contraindicated. </td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>Use of two serotonin modulators, such as zolmitriptan and lithium, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00934">Maprotiline</a></td><td>Use of two serotonin modulators, such as zolmitriptan and maprotiline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00353">Methylergometrine</a></td><td>Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, methylergonovine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. </td></tr><tr><td><a href="/drugs/DB00247">Methysergide</a></td><td>Possible severe and prolonged vasoconstriction</td></tr><tr><td><a href="/drugs/DB04896">Milnacipran</a></td><td>Use of two serotonin modulators, such as zolmitriptan and milnacipran, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00370">Mirtazapine</a></td><td>Use of two serotonin modulators, such as zolmitriptan and mirtazapine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01171">Moclobemide</a></td><td>The MAO inhibitor, moclobemide, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing moclobemide are contraindicated. </td></tr><tr><td><a href="/drugs/DB00952">Naratriptan</a></td><td>Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and naratriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.</td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Use of two serotonin modulators, such as zolmitriptan and nafazodone, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>Use of two serotonin modulators, such as zolmitriptan and nortriptyline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00715">Paroxetine</a></td><td>Use of two serotonin modulators, such as zolmitriptan and paroxetine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB01186">Pergolide</a></td><td>Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, pergolide, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. </td></tr><tr><td><a href="/drugs/DB00454">Pethidine</a></td><td>Use of two serotonin modulators, such as zolmitriptan and meperidine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>The MAO inhibitor, phenelzine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing phenelzine are contraindicated.</td></tr><tr><td><a href="/drugs/DB01168">Procarbazine</a></td><td>The MAO inhibitor, procarbazine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing procarbazine are contraindicated. </td></tr><tr><td><a href="/drugs/DB01069">Promethazine</a></td><td>Use of two serotonin modulators, such as zolmitriptan and promethazine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00344">Protriptyline</a></td><td>Use of two serotonin modulators, such as zolmitriptan and protriptyline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01367">Rasagiline</a></td><td>The MAO inhibitor, rasagiline, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing rasagiline are contraindicated. </td></tr><tr><td><a href="/drugs/DB00953">Rizatriptan</a></td><td>Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and rizatriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.</td></tr><tr><td><a href="/drugs/DB00118">S-Adenosylmethionine</a></td><td>Use of two serotonin modulators, such as zolmitriptan and S-adenosylmethionine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01037">Selegiline</a></td><td>The MAO inhibitor, selegiline, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing selegiline are contraindicated. </td></tr><tr><td><a href="/drugs/DB01104">Sertraline</a></td><td>Use of two serotonin modulators, such as zolmitriptan and sertraline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01105">Sibutramine</a></td><td>Use of sibutramine, which inhibits serotonin reuptake, and zolmitriptan, a serotonin 5-HT1D receptor agonist, may cause serotonin syndrome. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>Use of two serotonin modulators, such as zolmitriptan and St. John's Wort, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00669">Sumatriptan</a></td><td>Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and sumatriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.</td></tr><tr><td><a href="/drugs/DB06204">Tapentadol</a></td><td>Use of two serotonin modulators, such as zolmitriptan and tapentadol, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>The use of two serotonin modulators, such as zolmitriptan and tramadol, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>The MAO inhibitor, tranylcypromine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing tranylcypromine are contraindicated.</td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>Use of two serotonin modulators, such as zolmitriptan and trazodone, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Use of two serotonin modulators, such as zolmitriptan and trimipramine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Use of two serotonin modulators, such as zolmitriptan and venlafaxine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>